As pharmaceutical companies advance toward net zero, the greatest impact and complexity lies in the vast web of scope 3 emissions across suppliers, logistics, and product lifecycles. For many in the sector, these indirect emissions are largely driven by electricity and gas consumption that occur outside a company’s direct control. In other words, your suppliers’ scope 1 and 2 emissions.
To address these pressing topics, our climate strategy experts discussed:
- The evolving pharma scope 3 landscape
- High-impact decarbonisation levers across complex value chains
- A new way to scale credible decarbonisation amid evolving guidance
- How to communicate and account for the measurable reductions
